Meningococcal meningitis in India: An expert consensus on use of MCVs.

Hum Vaccin ImmunotherJul 14, 2026 (epub)
Clinical ResearchInfectious DiseasesPediatricsPreventive Medicine / Public HealthOpen access

Ashok Kumar Dutta, Rashna Dass Hazarika, K L Ravikumar et al.

✦ AI-curated · Sources linked

In 30 seconds

This consensus statement addresses invasive meningococcal disease (IMD) in India, highlighting its public health impact and vaccination strategies. Developed by 14 experts, the document reviews outbreaks from 1966 to 2022-2023, noting a case fatality ratio of 20.9% in Delhi. The consensus recommends MenACWY vaccination at 9-12 months with a booster at 10-11 years.

Key findings

  • IMD shows a bimodal age distribution, with 61.8% of cases in children under 5 years.
  • Serogroup A is predominant, with emerging serogroups C, W, and Y.
  • MenACWY conjugate vaccines provide 95.7-99.5% seroprotection across serogroups.
  • Systematic review indicates a 12.1% prevalence of IMD in epidemics.

Why it matters

Understanding the epidemiology and vaccination strategies for IMD is crucial for clinicians to improve patient outcomes and reduce mortality. Enhanced awareness and vaccination can help mitigate the public health burden of this disease.

Source

PubMed · PMID 42446494Free full text on PubMed Central

Published in Hum Vaccin Immunother. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.